Fanconi anemia gene editing by the CRISPR/Cas9 system. - Wikidata - awgldk - TriplyDB

Fanconi anemia gene editing by the CRISPR/Cas9 system.

Fanconi anemia gene editing by the CRISPR/Cas9 system.

http://www.wikidata.org/entity/Q35077625

about

Customizing the genome as therapy for the β-hemoglobinopathies The Rise of CRISPR/Cas for Genome Editing in Stem Cells Genome Editing and Its Applications in Model Organisms CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells Applications of CRISPR technologies in research and beyond.Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.The Simple Chordate Ciona intestinalis Has a Reduced Complement of Genes Associated with Fanconi Anemia.The CRISPR/Cas9 System and the Possibility of Genomic Edition for Cardiology Concise Review: Getting to the Core of Inherited Bone Marrow Failures.Sequence-specific DNA nicking endonucleases.Modeling Disease In Vivo With CRISPR/Cas9.Developmental history and application of CRISPR in human disease.CRISPR-Cas orthologues and variants: optimizing the repertoire, specificity and delivery of genome engineering tools.To CRISPR and beyond: the evolution of genome editing in stem cells.CRISPR-Cas9 technology and its application in haematological disorders.Gene editing and its application for hematological diseases.Modeling craniofacial and skeletal congenital birth defects to advance therapies.Emerging cellular and gene therapies for congenital anemias.CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes.Hematopoietic cell transplantation in Fanconi anemia: current evidence, challenges and recommendations.Therapeutic gene editing: delivery and regulatory perspectives CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi Anemia.Stem Cell Therapy for Fanconi Anemia.Viral Vectors, Engineered Cells and the CRISPR Revolution.Addressing challenges in the clinical applications associated with CRISPR/Cas9 technology and ethical questions to prevent its misuse.The Future of CRISPR Applications in the Lab, the Clinic and Society.Human genetic variation alters CRISPR-Cas9 on- and off-targeting specificity at therapeutically implicated loci.CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa.Bloom syndrome: research and data priorities for the development of precision medicine as identified by some affected families.Ex Vivo COL7A1 Correction for Recessive Dystrophic Epidermolysis Bullosa Using CRISPR/Cas9 and Homology-Directed Repair Targeted genome editing in acute lymphoblastic leukemia: a review Perspectives on gene therapy for Fanconi anemia

P2860

Q26751061-D2BF79A3-7782-4013-ACB9-0CA0FAB2BD90 Q26765852-0E155D35-4F73-4C94-B333-1135DF79F7A3 Q26772108-DFDC4E7D-9B09-4612-862D-D440CC7806AE Q33838956-9D3FAB75-0216-4215-A43E-02CE60CCF0A9 Q34539796-91E00E9F-F42D-4274-875D-0D8A1F6C1CB4 Q36326838-370A100C-29ED-4418-B097-C383091A43D9 Q36982306-5694053A-B551-48F4-BDD9-E41261AF26B6 Q37594531-7BFA397B-8B2E-4D15-97CA-4FBCC3332053 Q37633372-EA2DBF8E-A9B8-45E9-8B9C-08ED1ECED2B2 Q38583462-9FDD666F-9773-404F-8044-57D13D044B2C Q38598073-86DD3185-396E-493A-B134-45F06390356A Q38669948-7789917D-6FC0-4EB9-8660-EE3D10CB322C Q38716317-837EC2BD-58F2-4009-A2F4-FADAA2DD40B1 Q38788714-398A82B6-A1BB-4DCA-A67C-8E771DA78363 Q38822073-026C85A3-1A33-4DF0-BCC1-BF9669BAF22F Q38846192-97D71C9A-C115-4262-83F8-954A444BB4D5 Q38877817-69830B5C-35EB-4525-8008-F75840FCD79C Q38993825-A39E87A5-466A-45ED-B804-912E9C1C8DC7 Q39014648-9B915CA1-A513-49F4-B107-222F4C4C9ACA Q39032775-FA310005-3A9E-4EA4-A360-B540022759CB Q39230418-958869B7-7057-46BC-9D73-6D2FD3FFFDB8 Q42391311-5DD30AC8-7E00-4A82-B29C-EE2B3236FF5E Q45869566-96826DF7-3AD2-4D17-96C4-6866D8B80B11 Q45874356-5C7B41E1-408E-4B7D-B2E8-DE80555BE641 Q46208205-8F2AD2C3-9E8F-44EB-AF3F-C2A7617FC616 Q46262974-200E21F8-B194-40C5-9628-8B6F7A34B98B Q47327388-96F63228-6CEC-4DD2-B009-5BF1FD9F48F7 Q50897287-A7D599FE-581B-415C-9510-07735651C312 Q55362738-90B78787-343D-4816-9F80-CE04D3F533C3 Q57159704-DF3BB6CB-502B-48C5-8E56-2BA693345DE2 Q57175584-E237E9F8-9E83-4A3A-A887-728E6928D8D3 Q57952326-6E2AB22D-33C9-4755-AD22-0CE4931A6913

P2860

Fanconi anemia gene editing by the CRISPR/Cas9 system.

http://www.wikidata.org/entity/Q35077625

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Fanconi anemia gene editing by the CRISPR/Cas9 system.

@ast

Fanconi anemia gene editing by the CRISPR/Cas9 system.

@en

type

label

Fanconi anemia gene editing by the CRISPR/Cas9 system.

@ast

Fanconi anemia gene editing by the CRISPR/Cas9 system.

@en

prefLabel

Fanconi anemia gene editing by the CRISPR/Cas9 system.

@ast

Fanconi anemia gene editing by the CRISPR/Cas9 system.

@en

P1433

Q35077625-4EDAF286-723F-480A-8754-D1384A6F8288

P1476

Q35077625-0B779521-5EBA-44D6-AFE9-EBE04037B72A

P2093

Q35077625-157A967C-FC4A-453E-9D66-D675191C49DA

Q35077625-577BFBC6-4F91-457C-B0FA-927A87FD1B4C

Q35077625-5D92D797-8283-4EF5-B4AA-F989E91E80FA

Q35077625-62E1AC89-88CE-4830-A109-02DB88C5E117

Q35077625-A69CF380-C5EC-483C-8F45-E2739CC88164

Q35077625-B70F8918-B593-423B-A887-6A99A83C6301

Q35077625-D421658A-19A2-42D2-BD36-4418ED7B8A88

Q35077625-D745EC58-A962-4FED-8AE6-360296A76521

Q35077625-E48E94E1-4D84-4975-911C-4E8FFFE1A6DB

Q35077625-F0A58B71-3E33-4B52-A3AA-EFC875F146F1

P2860

Q35077625-0963B3E5-15D9-41AA-96C1-1DA7444EBF5A

Q35077625-0BC30CF6-BE64-4C08-9449-0D5BBED2178F

Q35077625-0BD207F0-BAA2-4DEF-A22B-230E2B9865E2

Q35077625-0D0CFC7A-609E-4AAF-8319-76D923BE472F

Q35077625-132CE94C-E7A7-452E-B682-92BC5B7F51CF

Q35077625-1B8DC476-39DC-4543-B148-6CD02ADF0F09

Q35077625-231DC5D2-1928-4A0C-B1AC-C5C5824A3541

Q35077625-24AB3F97-B36F-466B-9A6F-A936E6BDA91B

Q35077625-27B8A368-62D1-4576-B9B5-FEFC3BAB0B3D

Q35077625-2852400C-3C25-47F1-BA46-56D2358C425D

P304

Q35077625-FE346C43-6714-4127-82E7-E2971C8F47ED

P31

Q35077625-ED03B768-9077-472C-8CF9-C20D5CE9820F

P356

Q35077625-2E228506-1E6A-42CB-AE85-22453F99DD27

P433

Q35077625-CB5546E7-1D55-42B8-9F4F-2E93592AE04B

P478

Q35077625-6D2D3F8A-3581-41DF-A027-A1A6C1CBABA1

P50

Q35077625-56654CA5-5DD8-4CC9-B51E-FAA0730E5003

Q35077625-82379553-4149-4C5C-B325-CE2A87142C58

Q35077625-8AEFAFB0-D221-418C-81B0-6008585D2EF3

Q35077625-B6A8634F-53B7-4739-AB40-0BA1A9BB725D

P577

Q35077625-C65755C9-A420-4532-A449-F48D060D140C

P5875

Q35077625-6353778D-F14F-45C4-B81B-A1510E2D10F1

P698

Q35077625-C2FBFF33-DC90-461E-82ED-705CF67F1007

P921

Q35077625-3EBBFF7F-9D99-49BB-8263-05A0C9BACB00

P932

Q35077625-9C3E13CA-2F39-4183-B5F6-ED2456984221

P356

P1433

Human Gene Therapy

P1476

Fanconi anemia gene editing by the CRISPR/Cas9 system.

@en

P2093

Anthony P DeFeo

http://www.w3.org/2001/XMLSchema#string

Beau R Webber

http://www.w3.org/2001/XMLSchema#string

Bruce R Blazar

http://www.w3.org/2001/XMLSchema#string

Christof von Kalle

http://www.w3.org/2001/XMLSchema#string

J Keith Joung

http://www.w3.org/2001/XMLSchema#string

John E Wagner

http://www.w3.org/2001/XMLSchema#string

Jordan Jarjour

http://www.w3.org/2001/XMLSchema#string

Manfred Schmidt

http://www.w3.org/2001/XMLSchema#string

Mark J Osborn

http://www.w3.org/2001/XMLSchema#string

Richard Gabriel

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation of a novel myosin binding subunit of protein phosphatase 1 reveals a conserved mechanism in the regulation of actin cytoskeleton

The rearranged L-myc fusion gene (RLF) encodes a Zn-15 related zinc finger protein

RNA-guided human genome engineering via Cas9

Targeting DNA double-strand breaks with TAL effector nucleases

Multiplex genome engineering using CRISPR/Cas systems

Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells

Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification

RNA-programmed genome editing in human cells

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

The Fanconi anemia complementation group C gene product: structural evidence of multifunctionality

P304

114-126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/HUM.2014.111

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Daniel F Voytas

Amber N McElroy

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270221214

http://www.w3.org/2001/XMLSchema#string

P698

25545896

http://www.w3.org/2001/XMLSchema#string

P921

P932

4326027

http://www.w3.org/2001/XMLSchema#string